113 related articles for article (PubMed ID: 2898915)
1. Antineoplastic activity of two taxol derivatives on an ovarian tumor xenografted into nude mice.
Riondel J; Jacrot M; Nissou MF; Picot F; Bériel H; Mouriquand C; Potier P
Anticancer Res; 1988; 8(3):387-90. PubMed ID: 2898915
[TBL] [Abstract][Full Text] [Related]
2. Effects of free and liposome-encapsulated taxol on two brain tumors xenografted into nude mice.
Riondel J; Jacrot M; Fessi H; Puisieux F; Potier
In Vivo; 1992; 6(1):23-7. PubMed ID: 1352706
[TBL] [Abstract][Full Text] [Related]
3. [Action of taxol on human tumors transplanted in athymic mice].
Jacrot M; Riondel J; Picot F; Leroux D; Mouriquand C; Beriel H; Potier P
C R Seances Acad Sci III; 1983; 297(13):597-600. PubMed ID: 6143600
[TBL] [Abstract][Full Text] [Related]
4. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma.
Auzenne E; Donato NJ; Li C; Leroux E; Price RE; Farquhar D; Klostergaard J
Clin Cancer Res; 2002 Feb; 8(2):573-81. PubMed ID: 11839679
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the new vinca-alkaloid S 12363 alone or in combination with verapamil on a human multidrug resistant renal carcinoma xenograft.
Berlion M; Arvelo F; Leonce S; Bourgeois Y; Rigaudy P; Bizzari JP; Poupon MF
In Vivo; 1993; 7(5):399-405. PubMed ID: 7906553
[TBL] [Abstract][Full Text] [Related]
6. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
Yamamoto K; Kikuchi Y; Kudoh K; Hirata J; Kita T; Nagata I
Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition of a human ovarian tumor by a novel paclitaxel derivative in SCID mice.
Ahmad I; Masters GR; Schupsky JJ; Nguyen J; Ali S; Janoff AS; Mayhew E
Oncol Res; 1999; 11(6):273-80. PubMed ID: 10691029
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors.
Li C; Price JE; Milas L; Hunter NR; Ke S; Yu DF; Charnsangavej C; Wallace S
Clin Cancer Res; 1999 Apr; 5(4):891-7. PubMed ID: 10213226
[TBL] [Abstract][Full Text] [Related]
9. Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies.
Rose WC
J Natl Cancer Inst Monogr; 1993; (15):47-53. PubMed ID: 7912529
[TBL] [Abstract][Full Text] [Related]
10. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy.
Mayerhofer K; Kucera E; Zeisler H; Speiser P; Reinthaller A; Sevelda P
Gynecol Oncol; 1997 Jan; 64(1):109-13. PubMed ID: 8995557
[TBL] [Abstract][Full Text] [Related]
11. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
Klement G; Huang P; Mayer B; Green SK; Man S; Bohlen P; Hicklin D; Kerbel RS
Clin Cancer Res; 2002 Jan; 8(1):221-32. PubMed ID: 11801563
[TBL] [Abstract][Full Text] [Related]
12. Antitumor efficacy of solid dispersion of paclitaxel prepared by supercritical antisolvent process in human mammary tumor xenografts.
Shanmugam S; Park JH; Chi SC; Yong CS; Choi HG; Woo JS
Int J Pharm; 2011 Jan; 403(1-2):130-5. PubMed ID: 20974239
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
[TBL] [Abstract][Full Text] [Related]
14. [Assessment of the establishing individual protocol for effective chemotherapy of ovarian cancer--fundamental research using human tumor-nude mouse system].
Sawada M; Ozaki M; Hongo J; Hirota Y; Inagaki M
Nihon Sanka Fujinka Gakkai Zasshi; 1987 Oct; 39(10):1776-83. PubMed ID: 3429976
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a human ovarian carcinoma cell line: UCI 101.
Fuchtner C; Emma DA; Manetta A; Gamboa G; Bernstein R; Liao SY
Gynecol Oncol; 1993 Feb; 48(2):203-9. PubMed ID: 8428692
[TBL] [Abstract][Full Text] [Related]
16. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
[TBL] [Abstract][Full Text] [Related]
17. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
[TBL] [Abstract][Full Text] [Related]
19. Use of a surrogate marker (human secreted alkaline phosphatase) to monitor in vivo tumor growth and anticancer drug efficacy in ovarian cancer xenografts.
Bao R; Selvakumaran M; Hamilton TC
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):373-9. PubMed ID: 10985897
[TBL] [Abstract][Full Text] [Related]
20. [Taxol and ovarian adenocarcinomas].
Marty M; Extra JM; Culine S; Rousseau F
Pathol Biol (Paris); 1992 Nov; 39(9):834-5. PubMed ID: 1347165
[No Abstract] [Full Text] [Related]
[Next] [New Search]
